Since then, a limited number of GLP-1 RAs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of T2DM and, in certain cases, for the management of obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.